Independently studies on Finnish and Spanish CRC patients have shown that a high combined mutation rate of KRAS and BRAF in SAC (78.6% for the Finnish and 68.5% for the Spanish cohorts) indicates that mitogen-activated protein kinase (MAPK) activation plays a key role in the serrated pathway. This evidence concerns the gene BRAF and colorectal carcinoma.